Logo image
Back
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study
Journal article   Peer reviewed

The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study

Tiffany Sia, William Tew, Christopher Purdy, Dennis Chi, Andrew Menzin, John Lovecchio, Michael Bookman, David Cohn, Deanna Teoh, Michael Friedlander, …
Gynecologic oncology, Vol.173, pp.130-137
06/2023
DOI: 10.1016/j.ygyno.2023.03.018
PMCID: PMC10414765
PMID: 37148580
url
https://escholarship.org/content/qt3hk4x3p5/qt3hk4x3p5.pdfView
Open Access

Abstract

OBJECTIVE: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from surgery to chemotherapy, and rates of optimal cytoreduction. METHODS: Women enrolled in GOG 0182-ICON5 with stage III or IV epithelial ovarian cancer (EOC) who underwent surgery and chemotherapy between 2001 and 2004 were included. Patients were divided into ages <70 and ≥ 70 years. Baseline characteristics, treatment compliance, toxicities, and clinical outcomes were compared. RESULTS: We included a total of 3686 patients, with 620 patients (16.8%) ≥ 70 years. OS was 37.2 months in older compared to 45.0 months in younger patients (HR 1.21, 95% CI, 1.09-1.34, p < 0.001). Older patients had an increased risk of cancer-specific-death (HR 1.16, 95% CI, 1.04-1.29) as well as non-cancer related deaths (HR 2.78, 95% CI, 2.00-3.87). Median PFS was 15.1 months in older compared to 16.0 months in younger patients (HR 1.10, 95% CI, 1.00-1.20, p = 0.056). In the carboplatin/paclitaxel arm, older patients were just as likely to complete therapy and more likely to develop grade ≥ 2 peripheral neuropathy (35.7 vs 19.7%, p < 0.001). Risk of other toxicities remained equal between groups. CONCLUSIONS: In women with advanced EOC receiving chemotherapy, age ≥ 70 was associated with shorter OS and cancer specific survival. Older patients receiving carboplatin and paclitaxel reported higher rates of grade ≥ 2 neuropathy but were not more likely to suffer from other chemotherapy related toxicities. Clintrials.gov: NCT00011986.
 Aged Antineoplastic Combined Chemotherapy Protocols Carboplatin Carcinoma Disease-Free Survival Female Glandular and Epithelial Humans Neoplasm Staging Neoplasms Ovarian Epithelial Ovarian Neoplasms Paclitaxel Treatment Outcome

Details

Metrics

8 Record Views
7 Times Cited - Web of Science
Logo image